Michel Eid Farah

• Abstract

  To study the efficacy and cost-effectiveness of treatments with ranibizumab and bevacizumab against exudative age-related macular degeneration (AMD). Methods: A prospective randomized clinical trial to compare the efficacy of ranibizumab and bevacizumab for therapy against exudative AMD. Forty-five patients with exudative AMD will be allocated in three groups for an intensive three month …

  A study on the cost-effectiveness on the pharmacologic treatments for age-related macular degeneration, AP.R
• Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age related macular degeneration., AR.EXT
• Early rhegmatogenous retinal detachment following laser assited intrastromal keratomileusis for high myopia., AR.EXT

(Only some records are available in English at this moment)

• Abstract

  Age-related macular degeneration (ARMD) is the leading cause of visual loss and irreversible blindness in adults over 65 years old. The dry form of the disease is responsible for more than 85% of cases, resulting in social and economical impairment. Lutein and zeaxanthin are carotenoid pigments, which reach retina insignificant levels. Previous studies indicate the therapeutic potential o…

  Avaliação da densidade óptica de xantofilas em pacientes com degeneração macular relacionada à idade, BP.IC

• Abstract

  Diabetes mellitus is the most prevalent metabolic disease both in Brazil and the rest of the World and has several short, medium, and long-term complications. Pathologic changes in diabetic retinopathy are both macroangiopathic and microangiopathic. The disease is divided into proliferative and nonproliferative, both being responsible for much of the incidence of blindness worldwide. One …

  Development of proliferative retinopathy experimental model by intravitreal injection of VEGF, BP.IC

• Abstract

  Diabetic retinopathy (DR) is one of the leading causes of blindness in the labor age in developed countries. With clinical onset classically associated with vascular disorders, DR has treatments that have been shown limited and, sometimes, hold the little gain. Nevertheless, studies have indicated that neural loss may also occur in a very early stage of DR, even before any sign of vasculo…

  Early neural retinal changes in type 2 Diabetes Mellitus, BP.IC

(Only some records are available in English at this moment)